期刊文献+

宫内妊娠合并输卵管妊娠成功保胎一例分析 被引量:1

原文传递
导出
摘要 1临床资料患者33岁,因“试管移植术后32天,阴道不规则流血13天,腹痛1天”于2020年1月3日急诊入院。患者平素月经规律,周期3天,经期27~30天,经量中等,无痛经,末次月经:2019年11月16日。患者婚后3年未避孕、未怀孕。2019年11月18日于外院生殖中心行辅助生殖技术,11月28日取卵7枚,成熟卵7枚,正常受精7枚。可移植4枚胚胎均为优质胚胎,子宫内膜情况良好,2019年12月2日移植2枚桑葚胚。
出处 《哈尔滨医科大学学报》 CAS 2022年第2期195-198,共4页 Journal of Harbin Medical University
基金 黑龙江省青年科学基金资助项目(QC2018100)。
  • 相关文献

参考文献5

二级参考文献95

  • 1Papanikolaou EG, Pozzobon C, Kolibianakis EM, et al. Incidence and prediction of ovarian hyperstimulation syn- drome in women undergoing gonadoWopin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril, 2006, 85 (1):112-20.
  • 2Busso C, M, Garcia-Velasoa JA, etal. The non-ergot derived dopamine agonist quinagolide in pre- vention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-ennm)lled trial. Hum Reprod, 2010, 25(4):995-1004.
  • 3Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril, 2010, 94(2):389-400.
  • 4Al-Inany HG, Youssef MA, Aboulghar M, et al. Gonadotro- phin-releasing hormone antagonists for assisted reproduc- tive technology. Cochrane Database Syst Rev, 2011(5): CD001750.
  • 5Fiedler K, Ezcurra D. Predicting and preventing ovarian hyperslsulafion syndrome (OHSS): the need for individualized not standardized treatment. Reprod Biol Endoerinol, 2012, 10:32.
  • 6Tsoumpou I, Muglu J, G-elbaya TA, et al. Symposium: Update on prediction and management of OHSS. Optimal dose of HCG for final ooeyte maturation in IVF cycles: absence of evidence? Reprod Biomed Online, 2009, 19(1):52-8.
  • 7Lainas TG, Sfontouris IA, Zorzovilis IZ, et al. Management of severe early ovarian hyperstimulation syndrome by re- initiation of CmRH antagonist. Reprod Biomed Online, 2007, 15(4):408-12.
  • 8Lainas TG, Sfontouris IA, Zorzovilis IZ, et al. Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol. Reprod Biomed Online, 2009, 18( 1): 15-20.
  • 9Wada I, Matson PL, Home G, et al. Is continuation of a gouadotrophin-releasing hormone agonist (CmRHa) necessary for women at risk of developing the ovarian hyper-stimulation syndrome? Hum Reprod, 1992, 7(8): 1090-3.
  • 10Endo T, Hounma H, Hayashi T, et al. Continuation of GnRH agonist administration for 1 week, after hCG injection, pre- vents ovarian hyperstimtdation syndrome following elective cryopreservation ofaU pronucleate embryos. Hum Reprod, 2002, 17(10):2548-51.

共引文献381

同被引文献18

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部